2024
Asthma control in the United States: relationships between short-acting β2-agonist and systemic corticosteroid use
Chupp G, Murphy K, Gandhi H, Gilbert I, Bleecker E. Asthma control in the United States: relationships between short-acting β2-agonist and systemic corticosteroid use. Annals Of Allergy Asthma & Immunology 2024 PMID: 38740134, DOI: 10.1016/j.anai.2024.05.003.Peer-Reviewed Original ResearchMild to moderate diseaseSystemic corticosteroidsMild-to-moderateSevere asthmaUncontrolled asthmaSystemic corticosteroid exposureSystemic corticosteroid useAsthma control assessmentCorticosteroid useExacerbation historyRetrospective analysisSABA useUS patientsPrescription fillsPatientsLongitudinal accessAsthma controlDisease severityAsthmaDiseaseExacerbationPearson correlation coefficientHigh symptom burdenPatient severitySymptom burdenActivated sputum eosinophils associated with exacerbations in children on mepolizumab
Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X, Yan X, Sanders J, Visness C, Gill M, Gruchalla R, Liu A, Kattan M, Khurana Hershey G, Togias A, Becker P, Altman M, Busse W, Jackson D, Montgomery R, Chupp G. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal Of Allergy And Clinical Immunology 2024, 154: 297-307.e13. PMID: 38485057, DOI: 10.1016/j.jaci.2024.01.031.Peer-Reviewed Original ResearchAirway eosinophilsSputum eosinophilsPatients treated with mepolizumabPlacebo-controlled clinical trialAnti-IL-5 treatmentEffect of mepolizumabEosinophil subpopulationsSevere eosinophilic asthmaAnti-interleukin-5Expression of CD62LFrequency of exacerbationsEosinophilic asthmaActivation markersSputum samplesUnsupervised cluster analysisMepolizumabTreatment armsReduce exacerbationsCD62LClinical trialsExacerbationMass cytometryEosinophilsExacerbation riskIntracellular markers
2022
Asthma exacerbations during the pandemic: Time to rethink clinical markers
Ortega H, Katz L, Chupp G. Asthma exacerbations during the pandemic: Time to rethink clinical markers. Journal Of Allergy And Clinical Immunology Global 2022, 2: 97-100. PMID: 36281240, PMCID: PMC9581642, DOI: 10.1016/j.jacig.2022.09.003.Peer-Reviewed Original ResearchPrimary end pointAsthma exacerbationsClinical studiesClinical markersEnd pointCOVID-19 pandemicClinical trial enrollmentCoronavirus disease 2019 (COVID-19) pandemicNitric oxide levelsRecent clinical reportsDisease 2019 pandemicPrior exacerbationsPlacebo armFuture exacerbationsTrial enrollmentClinical trialsOxide levelsExacerbationClinical reportsClinical practiceCOVID-19Prior yearPandemicEnrollmentBest predictor117 Interleukin-6 and short-palate lung and nasal epithelium clone 1 fluctuations as sex-specific markers of acute cystic fibrosis exacerbation
Ayala A, Yin H, Khanal S, Niu N, Nunez M, Chupp G, Laguna T, Britto C. 117 Interleukin-6 and short-palate lung and nasal epithelium clone 1 fluctuations as sex-specific markers of acute cystic fibrosis exacerbation. Journal Of Cystic Fibrosis 2022, 21: s69. DOI: 10.1016/s1569-1993(22)00808-6.Peer-Reviewed Original Research
2020
Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure
Murphy K, Chipps B, Beuther D, Wise R, McCann W, Gilbert I, Eudicone J, Gandhi H, Harding G, Coyne K, Zeiger R, Board P, Kobernick A, Mohammad A, Cherry A, Fein A, Gaines A, Ramsey A, Michaud A, Palmer A, Kim A, Smith A, White A, Ricci A, Kettelhut B, Modena B, Stone B, Rolston B, Schnapf B, Krajicek B, Kraft C, Hopkins C, Natalie C, Anderson C, Czajkowski C, Arce D, Hamlin D, Hill D, Mares D, Pham D, Liao D, Simmons D, Johnson D, Jhaveri D, Maselli D, Kerwin E, Schuman E, Sher E, Bleecker E, Rakowski E, Hsu F, Averill F, Barsanti F, Gross G, Chupp G, Head G, Nasir H, Lee H, Barjaktarevic I, Cook J, Krainson J, Pearl J, Bellak J, Perez-Fernandez J, Rehm J, Trevor J, Most J, Hanson J, Blessing-Moore J, Biller J, Gedell J, Southard J, Chancellor J, Ilowite J, Romeo J, Mercado J, Fisher J, Greiwe J, Gregory K, Nadeau K, Shenoy K, Tan L, Stefanowicz L, Humes L, Bowers L, O’Connor M, Perez M, White M, Hegewald M, Wilson M, Sikora M, Morganroth M, Smith M, Farooqui N, Lesch N, Jain N, Parikh N, Hartog N, Luthin P, Stewart P, O’Connor P, Schochet P, Goldberg P, Patel P, Chinthrajah R, Sidhu R, Ayinla R, Brown R, Stadtler R, Wachs R, Balkissoon R, Duplantier R, Puente R, Settipane R, Mustafa S, Surani S, Jawad S, Adams S, Villegas S, Al-Farra S, Subramanian S, Bains S, Kelsen S, Wise S, Estrella-Eades S, Smith S, Qureshi T, Chen T, Kelbel T, Miller T, Jain V, Soong W, Soler X, Mattar Z. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2263-2274.e5. PMID: 32387166, DOI: 10.1016/j.jaip.2020.02.042.Peer-Reviewed Original ResearchConceptsAsthma controlAsthma Control Test scoresAsthma control toolPhysician-diagnosed asthmaCut pointsLogistic regression analysisAsthma impairmentExacerbation historyAsthma severityFuture exacerbationsTest-retest reliabilityRisk QuestionnaireSymptom impairmentAsthmaSpecialty practicePatientsRisk questionsGlobal InitiativeImpairmentAirQRisk increaseCharacteristic curveExacerbationRegression analysisComposite measure
2011
Pathways Activated during Human Asthma Exacerbation as Revealed by Gene Expression Patterns in Blood
Bjornsdottir US, Holgate ST, Reddy PS, Hill AA, McKee CM, Csimma CI, Weaver AA, Legault HM, Small CG, Ramsey RC, Ellis DK, Burke CM, Thompson PJ, Howarth PH, Wardlaw AJ, Bardin PG, Bernstein DI, Irving LB, Chupp GL, Bensch GW, Bensch GW, Stahlman JE, Karetzky M, Baker JW, Miller RL, Goodman BH, Raible DG, Goldman SJ, Miller DK, Ryan JL, Dorner AJ, Immermann FW, O'Toole M. Pathways Activated during Human Asthma Exacerbation as Revealed by Gene Expression Patterns in Blood. PLOS ONE 2011, 6: e21902. PMID: 21779351, PMCID: PMC3136489, DOI: 10.1371/journal.pone.0021902.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsAsthma exacerbationsBlood mononuclear cellsMononuclear cellsAnalysis of PBMCsAntigen-independent T-cell activationMajor unmet clinical needHuman asthma exacerbationsBronchoalveolar lavage samplesUnmet clinical needT cell activationStable asthmaExacerbation episodesGene expression signaturesRespiratory infectionsAirway tissueLavage samplesAdaptive immunityExacerbationAnalysis of covarianceCell activationInnate immunityLymphocyte activationLevel of expressionClinical need